Apr 15, 2020 / 07:30PM GMT
Mark Erlander - Trovagene, Inc. - Chief Scientific Officer
Thank you for joining. This is Mark Erlander. I am the Chief Scientific Officer for Trovagene Oncology. And we greatly appreciate your time today and the opportunity to tell you more about our Company and what we are doing.
Go to slide 3, really Trovagene is a clinical stage oncology therapeutics company and really the highlights of our Company are as follows. First of all, we are developing a drug called onvansertib. It's a first-in-class third generation PLK1 inhibitor that's oral and well tolerated.
Today I'm going to talk to you about three different trials that are ongoing demonstrating not only tolerability -- well, safe, but also efficacy. We have a predictive biomarker program for each of our trials which is useful, obviously, for identifying which patients have the greatest likelihood to respond.
And we really -- our approach is really the definition of precision medicine. It is really the combination -- we are using our drugs in combination with standard of care in three different indications. I'm going to
Trovagene Inc at Needham Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers